ATI RN
ATI Pharmacology Proctored Exam 2023
1. A client has a new prescription for transdermal patches. Which statement should the client make to indicate understanding of the instructions?
- A. I will clean the site with an alcohol swab before applying the patch.
- B. I will rotate the application sites weekly.
- C. I will apply the patch to an area of skin with no hair.
- D. I will place the new patch on the site of the old patch.
Correct answer: C
Rationale: The correct answer is C. Applying the patch to a hairless area of skin is essential for optimal medication absorption. Hair can interfere with the patch's adherence and effectiveness. It is important for the client to choose a site without hair to ensure proper delivery of the medication. Choices A, B, and D are incorrect because cleaning the site with an alcohol swab (Choice A) is a good practice but not the most crucial aspect for transdermal patch application. Rotating application sites weekly (Choice B) is more relevant for injections to prevent skin irritation or breakdown. Placing the new patch on the site of the old patch (Choice D) can lead to skin irritation and poor absorption due to a build-up of medication.
2. What is the therapeutic class of Valproate?
- A. Anticoagulant
- B. Antianxiety, benzodiazepines
- C. Anticonvulsant, vascular headache suppressant
- D. Mood stabilizer
Correct answer: C
Rationale: Valproate belongs to the therapeutic class of anticonvulsants. It is primarily used to manage seizures but is also effective in treating vascular headaches. Therefore, it is not classified as an anticoagulant, antianxiety medication, or mood stabilizer. Option A, anticoagulant, is incorrect as valproate does not have anticoagulant properties. Option B, antianxiety benzodiazepines, is incorrect as valproate is not primarily used to treat anxiety disorders with benzodiazepines. Option D, mood stabilizer, is incorrect as valproate is not classified as a mood stabilizer, although it can be used in some cases for mood disorders, its primary therapeutic class is anticonvulsant.
3. A client has a new prescription for Furosemide. Which of the following adverse effects should the nurse monitor?
- A. Hyperkalemia
- B. Hyponatremia
- C. Hypernatremia
- D. Hypercalcemia
Correct answer: B
Rationale: Furosemide is a diuretic that commonly causes hyponatremia (low sodium levels) due to its effect on sodium and water excretion. The nurse must closely monitor the client for signs of hyponatremia, such as weakness, confusion, and muscle cramps, and promptly intervene to prevent complications. Choices A, C, and D are incorrect because Furosemide is not associated with hyperkalemia, hypernatremia, or hypercalcemia. Understanding the medication's mechanism of action helps prioritize monitoring for potential adverse effects.
4. When educating a client with a new prescription for Losartan, which instruction should the nurse provide?
- A. Avoid consuming grapefruit juice.
- B. Take this medication with a full glass of water.
- C. Take this medication with food.
- D. Monitor for signs of dehydration.
Correct answer: D
Rationale: The correct answer is to instruct the client to monitor for signs of dehydration when taking Losartan. Losartan can lead to dehydration, so it is crucial for the client to watch out for symptoms like dry mouth, increased thirst, and reduced urine output. Monitoring for these signs can help prevent complications associated with dehydration while taking this medication. Choices A, B, and C are incorrect because Losartan is not known to have interactions with grapefruit juice, does not require a specific amount of water for intake, and can be taken with or without food.
5. A healthcare professional is educating a client who is starting therapy with gemcitabine. Which of the following findings should the healthcare professional instruct the client to report?
- A. Dyspnea
- B. Constipation
- C. Tinnitus
- D. Dry mouth
Correct answer: A
Rationale: The healthcare professional should instruct the client to report dyspnea since it can indicate pulmonary toxicity, a severe adverse effect associated with gemcitabine therapy. Monitoring and reporting dyspnea promptly can help in early detection and management of potential serious complications. Constipation, tinnitus, and dry mouth are not typically associated with gemcitabine therapy and are not urgent findings requiring immediate reporting.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access